Published in Curr Med Res Opin on April 01, 2010
Burden of treatment for chronic illness: a concept analysis and review of the literature. Health Expect (2013) 1.38
A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry (2012) 1.21
Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. BMC Psychiatry (2013) 0.88
Probing thalamic integrity in schizophrenia using concurrent transcranial magnetic stimulation and functional magnetic resonance imaging. Arch Gen Psychiatry (2012) 0.88
Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia. Neuropsychiatr Dis Treat (2015) 0.88
The ethics of elective psychopharmacology. Int J Neuropsychopharmacol (2011) 0.85
Resource utilization and cost in a commercially insured population with schizophrenia. Am Health Drug Benefits (2014) 0.83
Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database. Int Clin Psychopharmacol (2015) 0.82
Can the Direct Medical Cost of Chronic Disease Be Transferred across Different Countries? Using Cost-of-Illness Studies on Type 2 Diabetes, Epilepsy and Schizophrenia as Examples. PLoS One (2016) 0.81
Estimated economic benefits from low-frequency administration of atypical antipsychotics in treatment of schizophrenia: a decision model. Ann Gen Psychiatry (2012) 0.80
Health care resource use and direct medical costs for patients with schizophrenia in Tianjin, People's Republic of China. Neuropsychiatr Dis Treat (2015) 0.77
Conserved functional connectivity but impaired effective connectivity of thalamocortical circuitry in schizophrenia. Brain Connect (2012) 0.76
Treatment response, safety, and tolerability of paliperidone extended release treatment in patients recently diagnosed with schizophrenia. Ther Adv Psychopharmacol (2015) 0.75
Factors in Maintaining a Stable Patient-Physician Relationship among Individuals with Schizophrenia. Community Ment Health J (2017) 0.75
The Cost of Relapse in Schizophrenia. Pharmacoeconomics (2017) 0.75
Long-term mortality and medical care charges in patients with severe sepsis. Crit Care Med (2003) 2.39
The burden of chronic low back pain with and without a neuropathic component: a healthcare resource use and cost analysis. J Med Econ (2011) 1.19
The attributable clinical and economic burden of skin and skin structure infections in hospitalized patients: a matched cohort study. Diagn Microbiol Infect Dis (2009) 1.05
Costs of gastrointestinal events after outpatient opioid treatment for non-cancer pain. Ann Pharmacother (2010) 0.98
Comparison of the HUI3 with the SF-36 preference based SF-6D in a clinical trial setting. Value Health (2004) 0.96
Effects of morphine withdrawal on micro-opioid receptor-stimulated guanylyl 5'-[gamma-[35S]thio]-triphosphate autoradiography in rat brain. Eur J Pharmacol (2002) 0.91
Serum urate and incidence of kidney disease among veterans with gout. J Rheumatol (2013) 0.86
Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations. J Drugs Dermatol (2008) 0.84
Outcomes associated with initial versus later vancomycin use in patients with complicated skin and skin-structure infections. Pharmacoeconomics (2009) 0.84
Comparisons of hypertension-related costs from multinational clinical studies. Pharmacoeconomics (2004) 0.84
Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: a nationwide study in Hungary. Eur Neuropsychopharmacol (2013) 0.82
Comparing cost-effectiveness analyses of anti-hypertensive drug therapy for decision making: mission impossible? Value Health (2002) 0.82
Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat. Postgrad Med (2014) 0.81
Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension. Arch Intern Med (2003) 0.76
Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin. Br J Clin Pharmacol (2002) 0.75
Association Between Cognitive Function and Health Care Costs 3 Months and 6 Months After Initiating Antidepressant Medication for Depressive Disorders. J Manag Care Spec Pharm (2015) 0.75